Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Investigator: Ericka Greene, MD

Study Coordinator: Aramide Balogun

Status: Open Not Enrolling Number: NCT03920293

Phone: 713.441.6947

Protocol Number: Pro00021711


The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). [NCT03920293]
More to Explore